SCNI — Scinai Immunotherapeutics Share News
0.000.00%
Last trade - 00:00- $0.02m
- $3.28m
- $1.31m
Brief: Scinai Immunotherapeutics Announces $10 Million Standby Equity Purchase Agreement
Brief: Prof. Michael Schön, Director of Dermatology and Venereology at the University Medical Center Göttingen, Germany (UMG), Joins Scinai Immunotherapeutics' Scientific Advisory Board
Brief: Scinai Publishes Financial Results And Provides Business Updates
Brief: Scinai Announces Signing Of Loan Restructuring Agreement With European Investment Bank
Scinai's shares soar after announcing pre-clinical study results
Brief: Scinai Immunotherapeutics Announces Receipt of an Updated Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity
Brief: Scinai Immunotherapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement
BiondVax up on exclusive license for antibody development, sale
BiondVax rises on positive data on COVID drug preclinical study
U.S. STOCKS ON THE MOVE-Ford, Adobe, Accenture, Moderna, Avaya
U.S. STOCKS ON THE MOVE-Apple, Activision Blizzard, Manchester United
Brief: Biondvax Pharmaceuticals Ltd Files For ADS Offering Size Not Disclosed
BiondVax rises on deal to develop nanosized antibody therapies
BiondVax Pharma surges as former GSK exec joins board
Diagnostics, Williams-Sonoma, Cytokinetics
U.S. STOCKS ON THE MOVE-Vaccine makers, SeaChange, Voya Financial, BiondVax
U.S. STOCKS ON THE MOVE-Reliance Global, Allakos, Acasti Pharma, CalAmp Corp
BiondVax to develop nanosized COVID-19 antibody therapy, shares gain
Brief: Biondvax Pharmaceuticals Posts Quarterly Loss Per Share $0.005